(S)-(+)-Ibuprofen

• CAT Number: I003833
• CAS Number: 51146-56-6
• Molecular Formula: C13H18O2
• Molecular Weight: 206.3
• Purity: ≥95%
• Synonyms: (2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
• Target: COX
• Solubility: 100mMin DMSO;100mM in ethanol; dichloromethane, ethyl acetate, and methanol
• Storage: Room Temperature
• IC50: 13 uM (COX1); 370 uM (COX2)
• InChI: InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
• InChIKey: HEFNNWSXXWATRW-JTQLQIEISA-N
• SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(=O)O

(S)-(+)-Ibuprofen ((S)-Ibuprofen) (Cat No.: I003833) is the S(+)-enantiomer of Ibuprofen, a well-known medication. It is a potent inhibitor of both COX-1 and COX-2 enzymes, with IC50 values of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen is recognized for its analgesic, anti-inflammatory, anticancer, and antipyretic effects. This compound is widely used in the management of pain, inflammation, and fever. If you need to, please contact us in time, and we will reply to you as soon as possible within 24 hours.

Reference

[1]. Noreen Y, Ringbom T, Perera P, Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7.
[2]. Evans AM. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.
[3]. Nerurkar J, Beach JW, Park MO, Solubility of (+/-)-ibuprofen and S (+)-ibuprofen in the presence of cosolvents and cyclodextrins. Pharm Dev Technol. 2005;10(3):413-21.
[4]. Mayrhofer F. Efficacy and long-term safety of dexibuprofen [S(+)-ibuprofen]: a short-term efficacy study in patients with osteoarthritis of the hip and a 1-year tolerability study in patients with rheumatic disorders. Clin Rheumatol. 2001 Nov;20 Suppl 1:S22-9.
[5]. Bonabello A, Galmozzi MR, Canaparo R, Dexibuprofen (S+-isomer ibuprofen) reduces gastric damage and improves analgesic and antiinflammatory effects in rodents. Anesth Analg. 2003 Aug;97(2):402-8.